AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04707976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Care
Description: Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
Study NCT00423319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous, 40 mg, once daily, 5 weeks
Study NCT00423319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Oral tablets, 2.5 mg, twice daily, 5weeks
Study NCT00423319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin-matching placebo
Description: Administered as injection
Study NCT00423319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban-matching placebo
Description: Administered as oral tablets
Study NCT03490448 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercise and appropriate caloric control
Description: The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
Study NCT00823121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freezing embryos by vitrification
Description: vitrification by Cryotop method
Study NCT00823121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fresh embryo transfers
Description: fresh embryo transfers
Study NCT00823121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
Study NCT00823121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
Study NCT00823121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin (pregnyl)
Description: hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
Study NCT00336076 — intervention group
Intervention type: OTHER
Intervention: Collection of blood and bone marrow
Description: 5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
Study NCT04408599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer
Study NCT02202772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical instillation of Gemcitabine for 2 hours
Study NCT01617694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
Study NCT01617694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
Study NCT01617694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study NCT02522572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
Study NCT02522572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis will be administered based on group assignment.
Study NCT00388323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and biopsies
Description: blood and biopsies
Study NCT01478295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CuidaCare Intervention
Description: Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
Study NCT01478295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group/Usual Care:
Description: Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
Study NCT01478295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group/Usual Care:
Description: Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
Study NCT01617694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study NCT01385982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Actionable Test Result Management/Standardization
Description: The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
Study NCT00573157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
Study NCT00573157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
Study NCT00573157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
Study NCT00573157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
Study NCT02448147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous training
Description: Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
Study NCT03084848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
Study NCT00573157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
Study NCT00573157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
Study NCT03069898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRUE Dads
Description: The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
Study NCT01027013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide 2% ophthalmic suspension
Description: Instill one drop in each eye four times daily for 12 weeks.
Study NCT01027013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Instill one drop in each eye four times daily for 12 weeks.
Study NCT02072512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
Study NCT02072512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: goserelin 3.6mg subcutaneously every 28(± 3) days
Study NCT02072512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
Study NCT03130712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPC3-CART cells
Description: Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
Study NCT02500368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone hydrogel lens (test)
Description: contact lens
Study NCT02500368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A lens (control)
Description: contact lens
Study NCT00141856 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone care
Study NCT02828696 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: No prep treatment of worn dentition with CAD-CAM composite
Description: Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
Study NCT01007266 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assignment of a Lay Patient Partner
Study NCT01007266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assignment of a Lay Patient Partner
Study NCT01944696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
Study NCT00532818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and magnesium valproate
Description: Cisplatin + Topotecan plus hydralazine valproate
Study NCT00532818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cisplatin + Topotecan plus placebo
Study NCT02202772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravesical installation of Cisplatin for 2hours
Study NCT03795896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter
Description: The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
Study NCT02257541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study NCT02257541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT00140621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Study NCT02452541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prognostic tests
Description: * Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams
Study NCT03580174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal directed physiotherapy group
Description: Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
Study NCT03580174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy group
Description: Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
Study NCT03084848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
Study NCT03738722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
Study NCT03807388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMindCare Intervention Group
Description: Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
Study NCT03807388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 information
Description: Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 information
Description: Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 information
Description: Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 4 information
Description: Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 5 no information
Description: Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A Reminder
Description: One survey reminder at 14 days
Study NCT02961036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B Reminders
Description: Two survey reminders one at 14 days and one at 28 days
Study NCT02647476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunomodulating nutrition (Reconvan)
Description: protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
Study NCT02647476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutrition (Peptisorb)
Description: oligopeptide, low-fat, isocaloric, non-residue diet
Study NCT01382914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.12%
Description: twice daily, 10 ml, topical
Study NCT03210857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apnea performing
Description: The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made.
Study NCT02255669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: partially covered SEMS
Description: Used for palliation of inoperable malignant distal bile duct obstruction.
Study NCT02255669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fully covered SEMS
Description: Used for palliation of inoperable malignant distal bile duct obstruction.
Study NCT01944696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
Study NCT02283385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT
Description: 8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
Study NCT00970970 — intervention group
Intervention type: OTHER
Intervention: 89Zr bevacizumab PET scan
Description: Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
Study NCT00363883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00363883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03736447 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101 powder provided in capsules & sachets
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Study NCT03736447 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules & sachets
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study NCT02521545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Capsule
Study NCT04141488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: experimantal group
Description: Control Group
Study NCT04141488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimantal group
Description: Control Group
Study NCT04399317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow controlled ventilation (Evone-ventilator)
Description: The new ventilation technique will be applied
Study NCT00737685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, fludarabine , thymoglobulin
Description: cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
Study NCT02016729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 232
Description: Given an an oral tablet in escalating doses.
Study NCT02861287 — intervention group
Intervention type: OTHER
Intervention: Economic evaluation
Study NCT02016729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an oral tablet given in a fixed dose.
Study NCT03696940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
Description: Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
Study NCT03696940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
Study NCT01593228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550/BSI-201)
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Study NCT01593228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Study NCT01593228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL liposome injection
Description: Pharmaceutical form:Solution~Route of administration: Intravenous